JPRN-UMIN000012798
Completed
Phase 2
The safety and efficacy trial of nab-paclitaxel and trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer - The safety and efficacy trial of nab-paclitaxel and trastuzumab as neoadjuvant chemotherapy for HER2- positive breast cancer
ConditionsHER2-positive breast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- HER2-positive breast cancer
- Sponsor
- Tokyo Medical University Ibaraki Medical Center
- Enrollment
- 35
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Pregnant or lactating women 2\) Invasive cancer after completion of therapy(less than 5years ) 3\) Asynchronous bilateral breast cancer
Outcomes
Primary Outcomes
Not specified
Similar Trials
Terminated
Phase 1
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic HyperbilirubinemiaPancreatic NeoplasmsCholestasisNCT02267707Celgene1
Completed
Phase 2
A feasibility study of Nab-Paclitaxel followed by Anthracycline-based regimen as adjuvant chemotherapy for breast cancer.(SBCCSG-21)Primary breast cancerJPRN-UMIN000006084Saitama Breast Cancer Clinical Study Group(SBCCSG)30
Recruiting
Phase 2
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
Completed
Phase 2
Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.urothelial cancerJPRN-UMIN000015260Department of Urology, Saitama Medical Center, Saitama Medical University5
Completed
Not Applicable
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30